Medidata Solutions, Inc. (NASDAQ:MDSO) had its price target raised by investment analysts at J P Morgan Chase & Co to $87.00 in a report issued on Tuesday, The Fly reports. The brokerage currently has an “overweight” rating on the stock. J P Morgan Chase & Co’s price objective points to a potential upside of 8.49% from the stock’s current price.
A number of other brokerages have also recently weighed in on MDSO. Citigroup Inc. restated a “buy” rating and set a $94.00 target price (up from $77.00) on shares of Medidata Solutions in a report on Monday, July 10th. Piper Jaffray Companies raised their target price on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a report on Friday, July 7th. SunTrust Banks, Inc. raised their target price on shares of Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. BidaskClub upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Finally, Morgan Stanley set a $74.00 target price on shares of Medidata Solutions and gave the stock a “buy” rating in a report on Wednesday, June 14th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Medidata Solutions presently has an average rating of “Buy” and a consensus target price of $75.83.
Shares of Medidata Solutions (MDSO) traded down 1.00% on Tuesday, hitting $80.19. The company had a trading volume of 1,972,209 shares. Medidata Solutions has a 12 month low of $46.10 and a 12 month high of $85.92. The stock has a market cap of $4.52 billion, a PE ratio of 136.15 and a beta of 1.80. The company has a 50-day moving average of $74.17 and a 200 day moving average of $60.68.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. The business had revenue of $137.41 million during the quarter, compared to analysts’ expectations of $134.28 million. Medidata Solutions had a net margin of 6.72% and a return on equity of 11.05%. The business’s revenue was up 19.9% on a year-over-year basis. During the same period last year, the firm posted $0.24 earnings per share. Analysts anticipate that Medidata Solutions will post $1.29 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “J P Morgan Chase & Co Raises Medidata Solutions, Inc. (MDSO) Price Target to $87.00” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://stocknewstimes.com/2017/07/18/j-p-morgan-chase-co-raises-medidata-solutions-inc-mdso-price-target-to-87-00.html.
In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $69.46, for a total value of $347,300.00. Following the completion of the sale, the chief operating officer now owns 171,754 shares in the company, valued at approximately $11,930,032.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Taylor sold 5,639 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the completion of the sale, the director now owns 54,372 shares of the company’s stock, valued at approximately $3,994,167.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,139 shares of company stock valued at $1,259,466. Insiders own 5.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in MDSO. Acrospire Investment Management LLC acquired a new position in shares of Medidata Solutions during the first quarter valued at approximately $121,000. LS Investment Advisors LLC raised its position in shares of Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after buying an additional 1,021 shares during the period. World Asset Management Inc acquired a new position in shares of Medidata Solutions during the first quarter valued at approximately $201,000. Miles Capital Inc. acquired a new position in shares of Medidata Solutions during the first quarter valued at approximately $202,000. Finally, Oppenheimer & Close LLC acquired a new position in shares of Medidata Solutions during the first quarter valued at approximately $210,000.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
